Next generation vaccine biomarkers workshop October 30–31, 2014, Ottawa, Canada

From National Research Council Canada

DOIResolve DOI: https://doi.org/10.1080/21645515.2015.1083663
AuthorSearch for: 1; Search for: 1; Search for: ; Search for: ; Search for: ; Search for: 2; Search for: 1; Search for: 1; Search for: 1
Name affiliation
  1. National Research Council of Canada. Human Health Therapeutics
  2. National Research Council of Canada
FormatText, Article
Proceedings titleHuman Vaccines & Immunotherapeutics
ConferenceNext Generation Vaccine Biomarkers Workshop, October 30–31, 2014, Ottawa, Ontario, Canada
ISSN2164-5515
2164-554X
Volume11
Issue12
Pages2923–2930
SubjectAssay validation; Biomarkers; Correlates of protection; Immune monitoring; Immunization strategy; Surrogate markers; Vaccines; Vaccine safety; Vaccine efficacy
Abstract
Vaccine biomarkers are critical to many aspects of vaccine development and licensure, including bridging findings in pre-clinical studies to clinical studies, predicting potential adverse events, and predicting vaccine efficacy. Despite advances in our understanding of various biological pathways, and advances in systems analyses of the immune response, there remains much to learn about qualitative and quantitative aspects of the human host response to vaccination. To stimulate discussion and identify opportunities for collaborative ways to advance the field of vaccine biomarkers, A Next Generation Vaccine Biomarker workshop was held in Ottawa. The two day workshop, sponsored by the National Research Council Canada, Canadian Institutes of Health Research, Public Health Agency of Canada, Pfizer, and Medicago, brought together stakeholders from Canadian and international industry, government and academia. The workshop was grouped in themes, covering vaccine biomarker challenges in the pre-clinical and clinical spaces, veterinary vaccines, regulatory challenges, and development of biomarkers for adjuvants and cancer vaccines. The use of case studies allowed participants to identify the needs and gaps requiring innovation. The workshop concluded with a discussion on opportunities for vaccine biomarker discovery, the Canadian context, and approaches for moving forward. This article provides a synopsis of these discussions and identifies steps forward for advancing vaccine biomarker research in Canada.
Publication date
PublisherTaylor & Francis Group
LanguageEnglish
Peer reviewedYes
NPARC number23000050
Export citationExport as RIS
Report a correctionReport a correction
Record identifier51b8a1bd-536a-4d8d-aec7-709405264430
Record created2016-06-01
Record modified2020-04-22
Report a problem on this page
Date modified: